Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people aged 50 and over - PubMed (original) (raw)

Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people aged 50 and over

Jui-Kun Chiang et al. BMC Cardiovasc Disord. 2012.

Abstract

Background: Lipid accumulation product (LAP) has been advocated as a simple clinical indicator of metabolic syndrome (MS). However, no studies have evaluated the accuracy of LAP in predicting MS in Taiwanese adults. The aim of our investigation was to use LAP to predict MS in Taiwanese adults.

Methods: Taiwanese adults aged 50 years and over (n = 513) were recruited from a physical examination center at a regional hospital in southern Taiwan. MS was defined according to the MS criteria for Taiwanese people. LAP was calculated as (waist circumference [cm] - 65) × (triglyceride concentration [mM]) for men, and (waist circumference [cm] - 58) × (triglyceride concentration [mM]) for women. Simple logistic regression and receiver-operating characteristic (ROC) analyses were conducted.

Results: The prevalence of MS was 19.5 and 21.5% for males and females, respectively. LAP showed the highest prediction accuracy among adiposity measures with an area under the ROC curve (AUC) of 0.901. This was significantly higher than the adiposity measure of waist-to-height ratio (AUC = 0.813).

Conclusions: LAP was a simple and accurate predictor of MS in Taiwanese people aged 50 years and over. LAP had significantly higher predictability than other adiposity measures tested.

PubMed Disclaimer

Figures

Figure 1

Figure 1

ROC curves for adiposity measures in predicting MS using Taiwanese criteria (MS-TW). ROC, receiver-operating characteristic; AUC, area under the curve; LAP, lipid accumulation product; WHtR, waist-to-height ratio; BMI, body mass index; MS, metabolic syndrome.

References

    1. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Metabolic syndrome as a risk factor for coronary heart disease and stroke: an 11-year prospective cohort in Taiwan community. Atherosclerosis. 2007;194:214–221. doi: 10.1016/j.atherosclerosis.2006.07.033. - DOI - PubMed
    1. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–1132. doi: 10.1016/j.jacc.2010.05.034. - DOI - PubMed
    1. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629–636. doi: 10.1161/ATVBAHA.107.151092. - DOI - PubMed
    1. Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J. 2008;7:10. doi: 10.1186/1475-2891-7-10. - DOI - PMC - PubMed
    1. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol. 2010;25:375–384. doi: 10.1007/s10654-010-9459-z. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources